Brainsway(BWAY) - 2023 Q4 - Annual Report

D. Risk Factors · Clinical trials involve a lengthy and expensive process with an uncertain outcome, which may delay or cause us to abandon the development of Deep TMS for additional indications. · Our collaboration arrangements may not be successful, which could adversely affect our ability to develop and commercialize our products. Government Regulatory Risks · Our products and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to ...